Questions | Reviews
Brokers usually come in two varieties: the unique broker along with the impartial broker. An unbiased broker is an enterpriser who signifies many distinct insurance QuotesChimp at once. They're compensated through profits predicated on a percent of th...
by Audel in Audel, 03/06/2014
i would like to know infrared , mass , neuclear magnetic studies of halofantrine hydrochloride in order to understand its structure.I would also be pleased if i know about x-ray of halofantrine hydrochloride. synthesis of halofantrine hydrochloride is...
by zomi in Asia, 03/23/2006
Hi! This post could not be written any betetr! Reading this post reminds me of my old room mate! He always kept chatting about this. I will forward this article to him. Fairly certain he will have a good read. Thanks for sharing!
by Nahyr in Nahyr, 01/13/2014
Action/Kinetics: Blood schizonticide. Exact mechanism is unknown. At therapeutic doses, it prolongs QTc interval. The primary metabolite, n-butyl halofantrine, and the parent compound are equally active. Has wide interindividual variability in pharmacokinetics; probably due to erratic GI absorption. Peak plasma levels: 5-7 hr. When given with high fat foods, there is a 7-fold increase in peak plasma levels; a 3- to 5-fold increase in absorption seen if given 2 hr after a meal. t 1/2, distribution: 16 hr; t 1/2, terminal elimination: 6-10 days. Excreted through the feces.
Uses: Mild to moderate (100,000 or less parasites/mm 3) malaria due to Plasmodium falciparum or P. vivax.
Contraindications: Use in combination with drugs or clinical situations known to prolong QTc interval, family history of congenital QTc prolongation, in those who previously received mefloquine, or in those with known or suspected ventricular dysrhythmias, AV conduction disorders, or unexplained syncopal attacks. Lactation.
Special Concerns: The safety and efficacy in children, for use in prophylaxis of malaria, in cerebral malaria, or other complicated malaria forms have not been established. Clients with acute P. vivax are at risk of relapse because the drug does not eliminate the exoerythrocytic form; to eliminate the exoerythrocytic phase and avoid relapse, give the client an 8-aminoquinoline after initial halofantrine therapy.
Side Effects: GI: Abdominal pain, diarrhea, N&V, anorexia, abdominal distention, constipation, dyspepsia, stomatitis. CNS: Dizziness, headache, asthenia, confusion, depression, paresthesia, sleep disorder, convulsions. CV: Chest pain, palpitations, postural hypotension. Musculoskeletal: Rigors, myalgias, arthralgia, back pain. Miscellaneous: Cough, pruritus, fatigue, malaise, rash, urinary frequency, abnormal vision, tinnitus, decreased consciousness.
Laboratory Test Alterations: Hepatic transaminases. Hematocrit and platelet counts. and WBC counts.
Overdose Management: Symptoms: GI distress with abdominal pain, vomiting, cramping, diarrhea, palpitations, dehydration. Treatment: Induce vomiting and institute supportive treatment, including ECG monitoring. Treat dehydration with IV fluids.
Drug Interactions: Use with drugs known to prolong the QTc interval further prolongation of the QTc interval due to the possibility of a fatal reaction.
How Supplied: Tablets: 250 mg, 500 mg